Safety of transcutaneous auricular vagus nerve stimulation (taVNS): a systematic review and meta-analysis

Angela Yun Kim, Anna Marduy, Paulo S de Melo, Anna Carolyna Gianlorenco, Chi Kyung Kim, Hyuk Choi, Jae-Jun Song, Felipe Fregni, Angela Yun Kim, Anna Marduy, Paulo S de Melo, Anna Carolyna Gianlorenco, Chi Kyung Kim, Hyuk Choi, Jae-Jun Song, Felipe Fregni

Abstract

Transcutaneous auricular vagus nerve stimulation (taVNS) has been investigated as a novel neuromodulation tool. Although taVNS is generally considered safe with only mild and transient adverse effects (AEs), those specifically caused by taVNS have not yet been investigated. This systematic review and meta-analysis on taVNS aimed to (1) systematically analyze study characteristics and AE assessment, (2) characterize and analyze possible AEs and their incidence, (3) search for predictable risk factors, (4) analyze the severity of AE, and (5) suggest an evidence-based taVNS adverse events questionnaire for safety monitoring. The articles searched were published through April 7, 2022, in Medline, Embase, Web of Science, Cochrane, and Lilacs databases. In general, we evaluated 177 studies that assessed 6322 subjects. From these, 55.37% of studies did not mention the presence or absence of any AEs; only 24.86% of the studies described that at least one adverse event occurred. In the 35 studies reporting the number of subjects with at least one adverse event, a meta-analytic approach to calculate the risk differences of developing an adverse event between active taVNS and controls was used. The meta-analytic overall adverse events incidence rate was calculated for the total number of adverse events reported on a 100,000 person-minutes-days scale. There were no differences in risk of developing an adverse event between active taVNS and controls. The incidence of AE, in general, was 12.84/100,000 person-minutes-days of stimulation, and the most frequently reported were ear pain, headache, and tingling. Almost half of the studies did not report the presence or absence of any AEs. We attribute this to the absence of AE in those studies. There was no causal relationship between taVNS and severe adverse events. This is the first systematic review and meta-analysis of transcutaneous auricular stimulation safety. Overall, taVNS is a safe and feasible option for clinical intervention.

Conflict of interest statement

A.Y.K. has no conflicts of interest to declare. C.K.K., H.C. and J.S. are directly associated with Neurive Co, a company developing neuromodulation technologies, such as taVNS, to treat common brain diseases. A.C.G. is supported by the Federal University São Carlos and is a consultant for Neurive. P.S.dM. and A.M. are consultants for Neurive. F.F. is supported by NIH grants and is a consultant for Neurive.

© 2022. The Author(s).

Figures

Figure 1
Figure 1
Forest plot of the studies that reported the number of subjects reporting at least one adverse event in the active and sham groups.

References

    1. Bonaz B, Bazin T, Pellissier S. The vagus nerve at the interface of the microbiota-gut-brain axis. Front. Neurosci. 2018;12:49. doi: 10.3389/fnins.2018.00049.
    1. Bonaz B, Picq C, Sinniger V, Mayol JF, Clarençon D. Vagus nerve stimulation: From epilepsy to the cholinergic anti-inflammatory pathway. Neurogastroenterol. Motil. 2013;25:208–221. doi: 10.1111/nmo.12076.
    1. Goggins E, Mitani S, Tanaka S. Clinical perspectives on vagus nerve stimulation: Present and future. Clin. Sci. (Lond) 2022;136:695–709. doi: 10.1042/cs20210507.
    1. Ben-Menachem E, Revesz D, Simon BJ, Silberstein S. Surgically implanted and non-invasive vagus nerve stimulation: A review of efficacy, safety and tolerability. Eur. J. Neurol. 2015;22:1260–1268. doi: 10.1111/ene.12629.
    1. Bonaz B, et al. Chronic vagus nerve stimulation in Crohn's disease: A 6-month follow-up pilot study. Neurogastroenterol. Motil. 2016;28:948–953. doi: 10.1111/nmo.12792.
    1. Johnson RL, Wilson CG. A review of vagus nerve stimulation as a therapeutic intervention. J. Inflamm. Res. 2018;11:203–213. doi: 10.2147/jir.S163248.
    1. Asconapé JJ, Moore DD, Zipes DP, Hartman LM, Duffell WH., Jr Bradycardia and asystole with the use of vagus nerve stimulation for the treatment of epilepsy: A rare complication of intraoperative device testing. Epilepsia. 1999;40:1452–1454. doi: 10.1111/j.1528-1157.1999.tb02019.x.
    1. Giordano F, Zicca A, Barba C, Guerrini R, Genitori L. Vagus nerve stimulation: Surgical technique of implantation and revision and related morbidity. Epilepsia. 2017;58(Suppl 1):85–90. doi: 10.1111/epi.13678.
    1. Ventureyra EC. Transcutaneous vagus nerve stimulation for partial-onset seizure therapy. A new concept. Childs Nerv. Syst. 2000;16:101–102. doi: 10.1007/s003810050021.
    1. Farmer AD, et al. International consensus based review and recommendations for minimum reporting standards in research on transcutaneous vagus nerve stimulation (version 2020) Front. Hum. Neurosci. 2021 doi: 10.3389/fnhum.2020.568051.
    1. Redgrave J, et al. Safety and tolerability of Transcutaneous Vagus Nerve stimulation in humans; A systematic review. Brain Stimul. 2018;11:1225–1238. doi: 10.1016/j.brs.2018.08.010.
    1. Frangos E, Ellrich J, Komisaruk BR. Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. Brain Stimul. 2015;8:624–636. doi: 10.1016/j.brs.2014.11.018.
    1. Yap JYY, et al. Critical review of transcutaneous vagus nerve stimulation: Challenges for translation to clinical practice. Front. Neurosci. 2020 doi: 10.3389/fnins.2020.00284.
    1. Badran BW, et al. Laboratory administration of transcutaneous auricular vagus nerve stimulation (taVNS): Technique, targeting, and considerations. J. Vis. Exp. 2019 doi: 10.3791/58984.
    1. Llanos F, et al. Non-invasive peripheral nerve stimulation selectively enhances speech category learning in adults. NPJ Sci. Learn. 2020;5:12. doi: 10.1038/s41539-020-0070-0.
    1. Stefan H, et al. Transcutaneous vagus nerve stimulation (t-VNS) in pharmacoresistant epilepsies: A proof of concept trial. Epilepsia. 2012;53:e115–118. doi: 10.1111/j.1528-1167.2012.03492.x.
    1. Verma N, et al. Auricular vagus neuromodulation—A systematic review on quality of evidence and clinical effects. Front. Neurosci. 2021 doi: 10.3389/fnins.2021.664740.
    1. Wang L, et al. Transcutaneous auricular vagus nerve stimulators: A review of past, present, and future devices. Expert Rev. Med. Devices. 2022;19:43–61. doi: 10.1080/17434440.2022.2020095.
    1. Page MJ, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.
    1. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019.
    1. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based Ment. Health. 2019;22:153–160. doi: 10.1136/ebmental-2019-300117.
    1. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol. Med. 2008;3:17. doi: 10.1186/1751-0473-3-17.
    1. RStudioTeam. RStudio: Integrated Development Environment for R. RStudio, PBC, Boston, MA. (2022. ).
    1. CTEP. Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP, <> (2022. ).
    1. Fedak KM, Bernal A, Capshaw ZA, Gross S. Applying the Bradford Hill criteria in the 21st century: How data integration has changed causal inference in molecular epidemiology. Emerg. Themes Epidemiol. 2015;12:14. doi: 10.1186/s12982-015-0037-4.
    1. Sterne JAC, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898.
    1. Lehtimäki J, et al. Transcutaneous vagus nerve stimulation in tinnitus: A pilot study. Acta Otolaryngol. 2013;133:378–382. doi: 10.3109/00016489.2012.750736.
    1. Hein E, et al. Auricular transcutaneous electrical nerve stimulation in depressed patients: A randomized controlled pilot study. J. Neural Transm. (Vienna) 2013;120:821–827. doi: 10.1007/s00702-012-0908-6.
    1. Straube A, Ellrich J, Eren O, Blum B, Ruscheweyh R. Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): A randomized, monocentric clinical trial. J. Headache Pain. 2015;16:543. doi: 10.1186/s10194-015-0543-3.
    1. Jacobs HI, Riphagen JM, Razat CM, Wiese S, Sack AT. Transcutaneous vagus nerve stimulation boosts associative memory in older individuals. Neurobiol. Aging. 2015;36:1860–1867. doi: 10.1016/j.neurobiolaging.2015.02.023.
    1. Kreuzer PM, et al. Transcutaneous vagus nerve stimulation: Retrospective assessment of cardiac safety in a pilot study. Front. Psychiatry. 2012;3:70. doi: 10.3389/fpsyt.2012.00070.
    1. Hasan A, et al. Transcutaneous noninvasive vagus nerve stimulation (tVNS) in the treatment of schizophrenia: A bicentric randomized controlled pilot study. Eur. Arch. Psychiatry Clin. Neurosci. 2015;265:589–600. doi: 10.1007/s00406-015-0618-9.
    1. Bauer S, et al. Transcutaneous vagus nerve stimulation (tVNS) for treatment of drug-resistant epilepsy: a randomized, double-blind clinical trial (cMPsE02) Brain Stimul. 2016;9:356–363. doi: 10.1016/j.brs.2015.11.003.
    1. Stavrakis S, et al. Neuromodulation of inflammation to treat heart failure with preserved ejection fraction: A pilot randomized clinical trial. J. Am. Heart Assoc. 2022;11:e023582. doi: 10.1161/jaha.121.023582.
    1. Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting of adverse events in randomised controlled trials: A review. BMJ Open. 2019;9:e024537. doi: 10.1136/bmjopen-2018-024537.
    1. Golder S, Loke YK, Wright K, Norman G. Reporting of adverse events in published and unpublished studies of health care interventions: A systematic review. PLOS Med. 2016;13:e1002127. doi: 10.1371/journal.pmed.1002127.
    1. Silberstein SD, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016;87:529–538. doi: 10.1212/wnl.0000000000002918.
    1. Yuan H, Silberstein SD. Vagus Nerve and vagus nerve stimulation, a comprehensive review: Part II. Headache. 2016;56:259–266. doi: 10.1111/head.12650.
    1. Bermejo P, et al. Innervation of the human cavum conchae and auditory canal: Anatomical basis for transcutaneous auricular nerve stimulation. Biomed. Res. Int. 2017;2017:7830919. doi: 10.1155/2017/7830919.
    1. Tyler, W., Wyckoff, S., Hearn, T. & Hool, N. The Safety and Efficacy of Transdermal Auricular Vagal Nerve Stimulation Earbud Electrodes for Modulating Autonomic Arousal, Attention, Sensory Gating, and Cortical Brain Plasticity in Humans. (2019).
    1. Yakunina N, Kim SS, Nam EC. Optimization of transcutaneous vagus nerve stimulation using functional MRI. Neuromodulation. 2017;20:290–300. doi: 10.1111/ner.12541.
    1. Nemeroff CB, et al. VNS therapy in treatment-resistant depression: Clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology. 2006;31:1345–1355. doi: 10.1038/sj.npp.1301082.
    1. Keute M, Ruhnau P, Heinze HJ, Zaehle T. Behavioral and electrophysiological evidence for GABAergic modulation through transcutaneous vagus nerve stimulation. Clin. Neurophysiol. 2018;129:1789–1795. doi: 10.1016/j.clinph.2018.05.026.
    1. Muthulingam JA, et al. Cervical transcutaneous vagal neuromodulation in chronic pancreatitis patients with chronic pain: A randomised sham-controlled clinical trial. PLoS ONE. 2021;16:e0247653. doi: 10.1371/journal.pone.0247653.
    1. Capone F, et al. The effect of transcutaneous vagus nerve stimulation on cortical excitability. J. Neural. Transm. (Vienna) 2015;122:679–685. doi: 10.1007/s00702-014-1299-7.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する